# Safety and Efficacy Study of Glufosfamide in Patients With Recurrent Sensitive Small Cell Lung Carcinoma

> **NCT00435578** · PHASE2 · TERMINATED · sponsor: **Threshold Pharmaceuticals** · enrollment: 50 (estimated)

## Conditions studied

- Carcinoma, Small Cell Lung

## Interventions

- **DRUG:** Glufosfamide

## Key facts

- **NCT ID:** NCT00435578
- **Lead sponsor:** Threshold Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-02
- **Primary completion:** 2007-11
- **Final completion:** 2007-11
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2009-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00435578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00435578, "Safety and Efficacy Study of Glufosfamide in Patients With Recurrent Sensitive Small Cell Lung Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00435578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*